Hier bin ich wieder, hat jemand nen guten.... - 500 Beiträge pro Seite

[Prof.Knebbel]

Tipp?

[maxmues]

schönes Wochenende

[Wallgrekk]

Na klar. Check mal den Chart seit Jahresanfang aus!

Der Wert hat sich verdreifacht und in der Aktie steckt enorm viel Potential!


WKN 883147 Interneur. Pharmaceuticals Inc. Shares

Hier ein paar Infos:

Press Release

Interneuron`s PRO 2000 Shown to Protect Against Viral Infection in Primate Model of Sexual HIV Transmission

Results To Be Presented At Chicago AIDS Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 6, 2001--Researchers have demonstrated that a vaginal microbicide under development by Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC - news) can afford protection against viral infection in a rhesus monkey model of the sexual transmission of HIV (human immunodeficiency virus), the virus that causes AIDS (acquired immunodeficiency syndrome).

In a study supported by the National Institutes of Health (NIH) and conducted by the Southern Research Institute (SRI), most animals treated with the microbicide, known as PRO 2000, remained uninfected and healthy following exposure to a highly infectious dose of an HIV-like virus when compared to untreated animals. Complete findings from the study will be presented by Dr. Mark Lewis of SRI at the 8th Conference on Retroviruses and Opportunistic Infections in Chicago (February 4 - 8, 2001).

``These findings strengthen the rationale for developing PRO 2000 as a topical microbicide to prevent HIV infection,`` said Dr. Albert Profy, vice president of preclinical development at Interneuron. ``We believe this protection is conferred through prevention of HIV entry into susceptible human cells. The additional scientific evidence from the study provides further justification for expanded human testing.``

PRO 2000 is an antimicrobial compound formulated into a gel that is vaginally applied prior to sexual intercourse. The compound is designed to prevent the sexual transmission of HIV and other disease-causing microbes, including herpes simplex viruses, Chlamydia trachomatis and Neisseria gonorrhoeae.

In the SRI study, female rhesus macaque monkeys were pre-treated with a hormonal contraceptive to increase their susceptibility to infection. A month later, each animal in the treatment group received a single, intra-vaginal dose of PRO 2000 (at one of three strengths) and all animals were then challenged intra-vaginally with a hybrid simian-human immunodeficiency virus (SHIV), a simian virus that has the envelope of HIV. Because PRO 2000 appears to attack the HIV envelope, the use of SHIV rather than an unmodified simian virus may be more relevant to the human situation.

Two weeks after exposure, seven of seven untreated control monkeys showed evidence of infection, and all developed early signs of AIDS during the course of the study. By contrast, six of seven animals treated with 4% PRO 2000 remained uninfected and healthy over the 16-week course of the study. Five of seven animals treated with 2% PRO 2000 and two of seven treated with 0.5% PRO 2000 also remained uninfected and healthy. Of the five animals in the 0.5% group that appeared to be infected, all were able to control the virus, and none progressed to developing AIDS. The differences in levels of circulating virus between each of the PRO 2000 treated groups and the control group were all statistically significant (p less than 0.04).

The new findings confirm and extend the results of an earlier macaque study in which 4% PRO 2000 showed evidence for protection in a small number of animals. Though the precise relevance of the monkey model to the human situation has yet to be determined, the viral levels used to infect these animals are believed to be significantly higher than the dose to which women are typically exposed during a single sexual encounter. In previous animal studies, PRO 2000 was shown to prevent herpes infection in mice and to reduce pregnancy rates in rabbits.

PRO 2000 at the strengths found effective in the monkey study was previously judged to be safe and well tolerated in human Phase 1 clinical trials involving healthy, sexually abstinent women. Preliminary results from a NIH-supported Phase 1/Phase 2 clinical trial suggest the product has a promising safety profile in healthy, sexually active women as well. Interneuron believes that these data provide a strong rationale for accelerated Phase 2 and Phase 3 clinical testing to assess the long-term safety and protective efficacy of PRO 2000 in women at risk for HIV infection. A Phase 2 clinical trial of the product is scheduled to begin in Africa later this year, with support from the European Commission.

Cheers,

[Prof.Knebbel]

soll ich die boxe kaufen?

[Prof.Knebbel]

Kannst du mal überstzen? ich kann kein französisch.
Danke!

[Prof.Knebbel]

Was haltet ihr von den Tipps von NobberT?
Hat der Ahnung?

[Wallgrekk]

Interneur Phar hat einige Phase III Medikamente und ein Aidsmittel in Phase I/II.

Näheres zum Unternehmen kannst du auf der Homepage von Interneur. http://www.interneuron.com
erfahren (allerdings auch nur "französisch").

Die Sache ist die: Interneur Phar hat ein Medikament zur Bekämpfung von AIDS entwickelt, das gerade an Menschen in Afrika getetstet wird. Nach meinen Informationen ist das ein Gel, das im Genitalbereich aufgetragen wird und welches die Übertragung von Aids Viren verhindern soll.

Klartext: Sex ohne Gummi könnte bald wieder möglich werden!

Cheers,

[Prof.Knebbel]

@ Wallgrekk

Ich habe keinen Sex mehr.

[hirschauer]

n2h2 (NTWO) 924884
Data critical (dcca)
drkoop 923016

entweder steil nach oben oder steil nach unten.